Endo will own all candidates from the partnership.
Bangalore-based Jubilant Biosys and Endo Pharmaceuticals are collaborating to develop targets in the area of oncology. Their focus will be on delivering preclinical candidates that could be selected for joint clinical development.
Endo will own any compounds developed under the partnership and will be responsible for worldwide commercialization. Under an initial three-year agreement, Jubilant will receive from Endo research funding, success-based development milestones, and royalties.
Endo already has one cancer drug on the market: Valstar for the treatment of BCG-refractory bladder cancer. The firm has also filed for approval on its hypogonadism treatment. Its developmental pipeline comprises candidates for the prevention of HIV and STDs, pain, carcinoid syndrome, and stuttering.
AstraZeneca Taps Jubilant for Discovery Work (May 5, 2009)
Endo Inks Collaborations in Pain and Cancer (Feb. 11, 2009)
Endo Plans Diversification with $370M Offer for Indevus (Jan. 6, 2009)
ProStrakan Takes Over as North American Partner to Orexo from Endo (Jul. 31, 2008)
RxKinetix Subsumed by Endo Pharmaceuticals (Oct. 13, 2006)